Omran Ahmed Abu Aboud, D.V.M., M.Sc., M.P.V.M., Ph.D.

Specialties

Renal Cancer

Molecular Imaging

Targeted Therapy

Department

Internal Medicine

Title

  • Assistant Research Faculty

Genome and Biomedical Sciences Building

451 Health Sciences Dr
Davis, CA 95616
Driving Directions

Primary Phone:
530-752-2884

Additional Phone Numbers

Phone: 530-752-8868

Emails

Personal:
oaabuaboud@ucdavis.edu

Research/Academic Interests

Dr. Abu Aboud's research focuses on discovering novel diagnostic and therapeutic targets for solid tumors such as kidney cancer and for other hereditary kidney diseases such as ploy-cystic kidney disease.

He approaches these goals by utilizing omics approaches (metabolomics, proteomics and genomics) and developing animal models for these diseases.

Dr. Abu Aboud is also interested in metabolic reprogramming in cancer to validate and use amino acids as molecular imaging agents for PET scanning. 

Division

Nephrology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Education

M.Sc., Laboratory Animal Science, Gent University, Gent, Belgium 2005

D.V.M., Tripoli University, Tripoli, Libya 1995

M.P.V.M., Epidemiology, UC Davis, Davis CA 2015

Ph.D., Comparative Pathology, UC Davis, Davis CA 2015

Fellowships

Lawrence Livermore National Laboratory, Livermore CA 2014-2015

Internal Medicine, UC Davis Medical Center, Sacramento CA 2015-2017

Professional Memberships

American Association for Cancer Research

American Society of Nephrology

Honors and Awards

Richard C. Woodward Award for research excellence recipient at Internal Medicine, UC Davis, 2012

Select Recent Publications

Abu Aboud O, Habib SL, Trott JF, Stewart B, Liang S, Chaudhari AJ, Sutcliffe JL, Weiss RH. Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging. Cancer Res. 2017 Oct 11.

Hiromi Wettersten, Omran Abu Aboud, Primo Lara, and Robert Weiss. Metabolic reprogramming in renal cancer. Nature Reviews Nephrology. Published online 08 May 2017.

Vicki J. Hwang, Xia Zhou, Xiaonan Chen, Mohammad Mahjoub, William Senapedis, Erkan Baloglu, Omran Abu Aboud, Xiaogang Li, and Robert H. Weiss. Anti-cystogenic activity of a PAK4 inhibitor as a novel treatment for ADPKD. Kidney International. March 2017.

Josephine F. Trott, Omran Abu Aboud, Hiromi Wettersten, Benjamin Stewart, Grace Berryhill, Francisco Uzal, Russell C. Hovey, Jaime Modiano, and Robert H. Weiss  Attenuation of tryptophan metabolism enhances interferon therapy in kidney cancer: Is it time to revisit cytokine therapy?. Oncotarget. Aug 2016.

Abu Aboud O., Ching-Hsien Chen, William Senapedis, Erkan Baloglu, Christian Argueta, Robert H. Weiss. Specific inhibition of NAMPT and PAK4 by the small molecule KPT-9274 decreases kidney cancer growth. Mol Cancer Ther. 2016 Jul 7.

F. Trott, Abu Aboud O,Robert H. Weiss. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Cancer Res. 2015 Jun 15;75(12):2541-52.

Abu Aboud O, Wettersten HI and Weiss RH. Inhibition of PPAR-alpha induces cell cycle arrest and apoptosis and synergizes with glycolysis inhibition in kidney cancer cells. PLoS One 8: e71115. 2013.

Abu Aboud O, Donohoe D, Bultman S, Mark Fitch, Riiff T, Hellerstein M, RobeWeiss. PPARa inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth. Am J Physiol Cell Physiol. 2015 Jun 1;308(11):C890-8.

Abu Aboud O, Weiss RH. New Opportunities from the Cancer Metabolome. Clin Chem. 2013 Jan; 59(1):138-46.

Ganti S, Taylor SL, Abu Aboud O, Yang J, Evans C, Osier MV, Alexander DC, Kim K and Weiss RH. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res. 2012;72: 3471-3479.